Hana ʻo AASraw i nā pauka NMN a me NRC i ka nui!

Sunitinib Malate

Rating: Māhele:

Hoʻopau ʻo Sunitinib i ka hōʻailona cellular e ka māka ʻana i nā kinases tyrosine kinases (RTKs) he nui. Hoʻopili kēia me nā mea loaʻa i nā mea ulu i loaʻa i ka platelet (PDGF-Rs) a me nā mea loaʻa ulu ulu endothelial (VEGFRs), kahi mea i loko o ka angiogenesis tumo a me ka cell tumola hoʻonui.

Product Description

ʻO Characteristi maʻamaucs

Product Name Sunitinib Malate pauka
Kāleka CAS 341031-54-7
Ka Lā Molecular C22H27FN4O2
Papale ʻaʻa 398.474
'O Synonyms 557795-19-4;

Sutent;

Sunitinib malate pauka;

SU11248.

Keʻano ʻO ka pauma
Ka mālama a me ka lima lima E mālama iā ia i ka mahana wela a mamao aku mai ka wela a me ka momona.

 

Sunitinib Malate pauka wehewehe

ʻO Sunitinib (kūʻai ʻia ʻo Sutent e Pfizer, a i ʻike ʻia ma mua ʻo SU11248) he mea haʻi waha, liʻiliʻi liʻiliʻi, mea hoʻokipa i loaʻa ʻia me ka nui nui i loaʻa ʻia ka tyrosine kinase (RTK) i ʻāpono ʻia e ka FDA no ka mālama ʻana i ka carcinoma cell Renal (RCC) a me imatinib -resistant gastrointestinal stromal tumor (GIST) ma Ianuali 26, 2006. ʻO Sunitinib ka lāʻau lapaʻau maʻi ʻaʻai mua i ʻae ʻia i nā manawa like ʻelua.

 

ʻO Sunitinib Malate kaola pauma o ka hana

Ua pāpā ʻo Sunitinib i ka hōʻailona pūnaewele pūnaewele e ka ʻimi ʻana i mau receptor tyrosine kinases (RTKs).

Hoʻopili kēia i nā mea loaʻa āpau no ka mea ulu i loaʻa i ka platelet (PDGF-Rs) a me nā mea loaʻa ulu ulu endothelial vaskular (VEGFRs), kahi mea i loko o nā angiogenesis puʻupuʻu a me ka hoʻonui ʻana o ka cell tumora. No laila ke kaohi like ʻana o kēia mau pahuhopu no laila e hōʻemi ana i ka vascularization o ka tumo a hoʻonāukiuki i ka apoptosis cell cell cancer a pēlā e hopena ai ka shrinkage tumo

Hoʻopau pū ʻo Sunitinib iā CD117 (c-KIT), [2] ka receptor tyrosine kinase ((ke hoʻohana hewa ʻole ʻia e ka hoʻololi) e hoʻohuli i ka hapanui o nā ʻōpū o ka cell stromal cell gastrointestinal. Ua ʻōlelo ʻia ma ke ʻano he laina laina ʻelua no nā mea maʻi nāna nā ʻōpala e hoʻomohala. i ka C-KIT e pale aku iā lākou i ka imatinib, a i ʻole ka mea hiki ʻole ke ʻae i ka lāʻau.

 

Sunitinib Malate pauka noi

 Tumo stromal Gastrointestinal

E like me RCC, ʻaʻole pane ʻo GIST i ka chemotherapy maʻamau a i ʻole ka radiation. ʻO Imatinib ka ʻākena maʻi ʻaʻai mua i hōʻike maikaʻi ʻia no ka GIST metastatic a ua pani ʻia i kahi ulu nui i ka mālama ʻana i kēia maʻi laha akā paʻakikī.

 

 Meningioma

Ke aʻo ʻia nei ʻo Sunitinib no ka mālama ʻana i ka meningioma e pili ana me ka neurofibromatosis.

 

 Nā tumors neuroendocrine pancreatic

I Nowemapa 2010, ua ʻae ʻia ʻo Sutent mai ke Komikina ʻEulopa no ka mālama ʻana i nā tumora neuroendocrine pancreatic ʻokoʻa maikaʻi me ka ulu ʻana o ka maʻi i nā mākua.

 

 Ka maʻi kanesa puʻupaʻa

Ua ʻae ʻia ʻo Sunitinib no ka mālama ʻana i ka RCC metastatic. ʻO nā koho lapaʻau ʻē aʻe i kēia hoʻonohonoho ʻo pazopanib (Votrient), sorafenib (Nexavar), temsirolimus (Torisel), interleukin-2 (Proleukin), everolimus (Afinitor), bevacizumab (Avastin), a me aldesleukin.

 

Sunitinib Malate pauka Nā ʻaoʻao a me nā ʻōlelo aʻoaʻo

Kuhi ʻia nā hanana kūpilikiʻi Sunitinib me kahi mea hiki ke mālama ʻia a me nā hanana haʻahaʻa haʻahaʻa haʻahaʻa haʻahaʻa.

ʻO nā hanana kūpili maʻamau e pili pū ana me ka sunitinib therapy ka luhi, ka maʻi pākī, nausea, anorexia, hypertension, kahi ʻili melemele, ka ʻili o ka ʻili wāwae wawae, a me ka stomatitis. I ka placebo-kāohi Phase III GIST hoʻopaʻa haʻawina, nā hopena maikaʻi ʻole i hana pinepine ʻia me ka sunitinib ma mua o ka placebo me ka maʻi diarrhea, anorexia, ka hoʻoliʻiliʻi o ka ʻili, mucositis / stomatitis, astenia, ka ʻono i hoʻololi ʻia, a me ka constipation.

Koi ʻia nā hoʻoliʻiliʻi hana ma 50% o nā maʻi i hoʻopaʻa ʻia i ka RCC i mea e mālama ai i nā mea ʻona nui o kēia agena.

Kūpilikiʻi (papa 3 a 4 paha) nā hanana maikaʻi ʻole ma ≤10% o nā mea maʻi a komo pū me ke kiʻekiʻe kiʻekiʻe, nāwaliwali, astenia, diarrhea, a me ka chemotherapy-induced acral erythema. ʻO nā kūlohelohe lab e pili pū ana me ka sunitinib therapy me lipase, amylase, neutrophils, lymphocytes, a me nā platelet. Ua pili pū ʻia ka hypothyroidism a me ka erythrocytosis hiki ke hoʻohuli ʻia me sunitinib.

 

Reference

[1] US Food and Drug Administration (2006). "ʻAe ʻo FDA i ka lāʻau hou no ka maʻi ʻaʻai gastrointestinal a me ka maʻi puʻuwai".

[2] Hartmann JT, Kanz L (Nowemapa 2008). "Sunitinib a me nā lauoho depigmentation o ka manawa ma muli o ka kaohi c-KIT manawa". Arch Dermatol. 144 (11): 1525-6. hana: 10.1001 / archderm.144.11.1525. PMID 19015436. Waihona ʻia mai ke kumu ma 2011-07-25.

[3] Quek R, George S (Pepeluali 2009). "ʻO ke tumomoma stromal gastrointestinal: kahi nānā olakino". Hematol. ʻO Oncol. Kalinika ʻAkau ʻAkau 23 (1): 69-78, viii. hana: 10.1016 / j.hoc.2008.11.006. PMID 19248971.

[4] Blay JY, Reichardt P (Iune 2009). "ʻO ka tumom gastromestinal stromal tumom maʻEulopa: kahi loiloi o nā ʻōlelo hoʻomaikaʻi hoʻomaikaʻi hou". ʻO ka loea Rev Anticancer Ther. 9 (6): 831–8. hana: 10.1586 / era.09.34. PMID 19496720. S2CID 23601578.

[5] Gan HK, Seruga B, Knox JJ (Iune 2009). "Sunitinib i nā tumors paʻa". ʻO nā lāʻau lapaʻau Opin Investig Expert. 18 (6): 821–34. hana: 10.1517 / 13543780902980171. PMID 19453268. S2CID 25353839.

[6] "Ke kuhikuhi nei i ka ʻike no Sutent (sunitinib malate pauka)". Pfizer, Inc, New York NY.